Retrospective observational cohort study to compare medication adherence at 12 months between patients in Japan with dyslipidemia and/or hypercholesterolemia (familial and non-familial hypercholesterolemia) who newly initiate inclisiran versus those who newly initiate evolocumab.
Study Type
OBSERVATIONAL
Enrollment
3,600
Medication adherence at 12 months : proportion of days covered (PDC) within a period that the patient is persistent
Adherence is defined using proportion of days covered (PDC) within a period that the patient is persistent: calculated as the number of days covered by the target drug (inclisiran in the exposure group, evolocumab in the control group) during the 12 months follow-up period, divided by 365 days.
Time frame: 12 months
Proportion of patients with good adherence
Proportion of patients with good adherence at 12 months follow-up period, defined as PDC ≥ 80%.
Time frame: 12 months
Number of patients by demographic category
Time frame: Baseline
Time to discontinuation
The date of discontinuation of first treatment drug will be considered as the date of outcome occurrence.
Time frame: 12 months
Proportion of patients receiving LLTs
Proportion of patients receiving LLTs (statin only/ezetimibe only/statin and ezetimibe) during the baseline period and 12 months follow-up period
Time frame: 12 months
Novartis Pharmaceuticals
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.